#125 – The Scariest and Baddest: Burkholderia, Achromobacter, and Elizabethkingia

About this episode

The episode discusses the resistance mechanisms and characteristics of Burkholderia, Achromobacter, and Elizabethkingia, featuring insights from multiple experts.

Drs. Maria Mojica, Robert Bonomo, and Ryan Shields join Dr. Erin McCreary (@erinmccreary) for a Halloween special reviewing the scariest resistance mechanisms and baddest bugs – Burkholderia spp., Achromobacter spp., and Elizabethkingia spp. Never have beta lactamase enzymes and other complexities been explained so hauntingly well. We don’t want to spook you, but these environmental, opportunistic pathogens are found around the globe. While we hope you don’t encounter them, take a listen to prepare in case one jumps out in your practice! This episode was sponsored by an unrestricted grant from Shionogi Inc. References: Spencer HK, Spitznogle SL, Borjan J, Aitken SL. An Overview of the Treatment of Less Common Non-Lactose-Fermenting Gram-Negative Bacteria. Pharmacotherapy. 2020 Sep;40(9):936-951. doi: 10.1002/phar.2447. Epub 2020 Aug 14. PMID: 32687670 . Defining antimicrobial susceptibility testing methods and breakpoints among Achromobacter species SIDP 2025 Webinar | Mind the Gap: CLSI M100 Updates to Optimize Stewardship and Patient Care Outcomes Yasmin M, Rojas LJ, Marshall SH, Hujer AM, Cmolik A, Marshall E, Boucher HW, Vila AJ, Soldevila M, Diene SM, Rolain JM, Bonomo RA…

People in this episode

Host: Dr. Erin McCreary

Guests: Dr. Maria Mojica, Dr. Robert Bonomo, Dr. Ryan Shields

Topics covered

• antimicrobial resistance
• opportunistic pathogens
• beta lactamase enzymes
• Burkholderia
• Achromobacter
• Elizabethkingia
• healthcare preparation

Keywords

• Burkholderia
• Achromobacter
• Elizabethkingia
• antimicrobial resistance
• beta lactamase
• opportunistic pathogens
• healthcare

Sponsors

Shionogi Inc.

Mentioned in this episode

Books & works: An Overview of the Treatment of Less Common Non-Lactose-Fermenting Gram-Negative Bacteria, Characterization of a Novel Pathogen in Immunocompromised Patients: Elizabethkingia anophelis -Exploring the Scope of Resistance to Contemporary Antimicrobial Agents and β-lactamase Inhibitors

More episodes of Breakpoints

• #136 – GAS, Streptococcus pyogenes: Call It What You Want, It’s Got a Big Reputation · June 5, 2026 · 1h 25m
• #135 – Stewie Struggles: Small Hospital Edition · May 22, 2026 · 1h 3m
• #134 – ESCMID Global Trials: PETER PEN and ASTARTE · May 8, 2026 · 1h 3m
• #133 – Trash talk: Earth Day Special on Healthcare Sustainability and Stewardship · April 17, 2026 · 48 min
• #132 – Complicated UTIs: What’s Crystal Clear & What’s Still Cloudy · March 13, 2026 · 1h 9m
• #131 – Drawing the Line: The Writing, Reach, and Limits of Guidelines · February 22, 2026 · 1h 0m